Posted in M&A / Deals Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy March 31, 2026 BioSpace In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in M&A / DealsNephrologyRead full story